Clinical Relevance of Transurethral Resection of the Prostate in "Asymptomatic" Patients with an Elevated Prostate-Specific Antigen Level

European Urology

Volumn 52, Issue 3, 2007, Pages 819-826

  van Renterghem, Koenraad ^a   Van Koeveringe, Gommert ^b   Achten, Ruth ^a   Van Kerrebroeck, Philip ^b  

^a VIRGA JESSE HOSPITAL   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Benign prostatic enlargement; Benign prostatic hyperplasia; Diagnosis; Lower urinary tract symptoms; Prostate cancer; Prostate specific antigen; Transition zone; Transurethral resection of the prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; URODYNAMICS;

AGED; BIOPSY; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME;

EID: 34547213884     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.055     Document Type: Article

References (30)

1. Partin A.W., and Oesterling J.E. The clinical usefulness of prostate specific antigen: update 1994. J Urol 152 (1994) 1358-1368
2. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
3. Durkan G.C., Sheikh N., Johnson P., Hildreth A.J., and Greene D.R. Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol. BJU Int 89 (2002) 33-39
4. Boccon-Gibod L., van der Kwast T.H., Montironi R., Boccon-Gibod L., and Bono A. Handling and pathology reporting of prostate biopsies. Eur Urol 46 (2004) 177-181
5. Rosai J. Ackerman's surgical pathology. ed. 9 (2004), Mosby Year Book, St. Louis
6. Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I.A. WHO blue book: World Health Organization classification of tumors. Pathology and genetics of tumours of the urinary system and male genital organs (2004), IARC Press, Lyon, France
7. Kirby R.S. The clinical assessment of benign prostatic hyperplasia. Cancer 70 (1992) 284-290
8. Fleshner N.E., and Fair W.R. Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol 157 (1997) 556-558
9. Djavan B., Ravery V., Zlotta A., et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol 166 (2001) 1679-1683
10. Raaijmakers R., Kirkels W.J., Roobol M.J., Wildhagen M.F., and Schröder F.H. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60 (2002) 826-830
11. Abrams P., Blaivas J., Griffiths D.J., et al. The objective evaluation of bladder outflow obstruction. In: Cockett A.T.K., Khoury S., Aso Y., et al. (Eds). Proceedings of the 2nd international consultation on benign prostatic hyperplasia (1993), Jersey Scientific Communication, Jersey 153-209
12. Laguna P., and Alivizatos G. Prostate specific antigen and benign prostatic hyperplasia. Curr Opin Urol 10 (2000) 3-8
13. Claridge M., and Shuttleworth K.E. The dynamics of obstructed micturition. Invest Urol 25 (1964) 188-199
14. Mochtar C.A., Kiemeney L.A., Laguna M.P., et al. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology 65 (2005) 300-305
15. Laniado M.E., Ockrim J.L., Marronaro A., Tubaro A., and Carter S.S. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 94 (2004) 1283-1286
16. Roehrborn C.G., McConnell J., Bonilla J., et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 163 (2000) 13-20
17. Marberger M.J., Andersen J.T., Nickel J.C., et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 38 (2000) 563-568
18. Reich O., Gratzke C., and Stief C.G. Techniques and long-term results of surgical procedures for BPH. Eur Urol 49 (2006) 970-978
19. Muntener M., Aellig S., Kuttel R., Gehrlach C., Hauri D., and Strebel R.T. Peri-operative morbidity and changes in symptom scores after transurethral prostatectomy in Switzerland: results of an independent assessment of outcome. BJU Int 98 (2006) 381-383
20. Bratt O. The difficult case in prostate cancer diagnosis-when is a "diagnostic TURP" indicated?. Eur Urol 49 (2006) 769-771
21. Puppo P., Introini C., Calvi P., and Naselli A. Role of transurethral resection of the prostate and biopsy of the peripheral zone in the same session after repeated negative biopsies in the diagnosis of prostate cancer. Eur Urol 49 (2006) 873-878
22. Zigeuner R., Schips L., Lipsky K., et al. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology 62 (2003) 883-887
23. Radhakrishnan S., Dorkin T.J., Sheikh N., and Greene D.R. Role of transition zone sampling by TURP in patients with raised PSA and multiple negative transrectal ultrasound-guided prostatic biopsies. Prostate Cancer Prostatic Dis 7 (2004) 338-342
24. Kitamura H., Masumori N., Tanuma Y., et al. Does transurethral resection of the prostate facilitate detection of clinically significant prostate cancer that is missed with systematic sextant and transition zone biopsies?. Int J Urol 9 (2002) 95-99
25. Philip J., Dutta R.S., Scally J., Foster C.S., and Javle P. Importance of TURP in diagnosing prostate cancer in men with multiple negative biopsies. Prostate 64 (2005) 200-202
26. Rovner E.S., Schanne F.J., Malkowicz S.B., and Wein A.J. Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies. J Urol 158 (1997) 138-141
27. Shannon B.A., McNeal J.E., and Cohen R.J. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. Pathology 35 (2003) 467-471
28. Greene D.R., Wheeler T.M., Egawa S., Dunn J.K., and Scardino P.T. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 146 (1991) 1069-1076
29. Reissigl A., Pointner J., Strasser H., Ennemoser O., Klocker H., and Bartsch G. Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate 30 (1997) 130-135
30. Merrill R.M., and Wiggins C.L. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 7 (2002) 213-219